Leerink Swann Initiates Trillium Therapeutics At Outperform

Analysts at Leerink Swann initiated coverage on Trillium Therapeutics Inc (NASDAQ: TRIL) with a Outperform rating.

The target price for Trillium Therapeutics is set to $29.

Trillium Therapeutics shares have gained 132.57 percent over the past 52 weeks, while the S&P 500 index has surged 13.28 percent in the same period.

Trillium Therapeutics' shares closed at $24.21 on Friday.